Stem Cell Treatment of Peyronie´s Disease.

Launched by ESBJERG HOSPITAL - UNIVERSITY HOSPITAL OF SOUTHERN DENMARK · Feb 23, 2021

Keywords

ClinConnect Summary

No description provided

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Acquired penile curvature \>30 and \<90 degrees associated with a palpable penile plaque on physical examination.
• • 2. One or several plaques at ultrasound screening.
• • 3. Willingness to attend follow-up at 1, 3, 6 and 12 months.
• • 4. Understand and speak Danish.
• • 5. Men \> 18 years of age
• Exclusion Criteria:
• Patients may not be:
• • 1. Taking the medication Coumadin, Warfarin or NOAK (new oral anticoagulant).
• • 2. Unable to achieve adequate erection with penile injection to access degree of curvature.
• • 3. Undergoing definitive treatment for prostate cancer, bladder cancer, or other pelvic malignancies including surgery, external beam radiation therapy, brachytherapy, and cryotherapy.
• • 4. With prior history of prostate cancer, hematologic disorders, chronic liver disease including cirrhosis and hepatitis C, disorders affecting the immune system, including infection with the human immunodeficiency virus, or psychiatric disorders including but not limited to major depression, schizophrenia, bipolar disease.
• • 5. With a history of cerebrovascular incidents, a history of deep venous thrombosis within the past 5 years or a history of untreated or severe sleep apnoea.
• • 6. With a clinically significant abnormal, results that would put the subject at increased risk or compromise the integrity of the study data, in the opinion of the investigator. Blood tests will be analysed for HIV, Hepatitis B and C and syphilis and those applicable within guidelines of the department.
• • 7. Involved with any other projects with an investigational drug within 30 days.
• • 8. In treatment for alcohol or drug abuse within six months.
• • 9. With congenital deviation of penis.
• • 10. Within six months treated with Collagenase, ESWT and/or other therapeutic injection in the plaque treatment for PD.